# Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

> **NCT00638118** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 48 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** Fexofenadine

## Key facts

- **NCT ID:** NCT00638118
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00638118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00638118, "Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00638118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*